A liquid biopsy signature predicts lymph node metastases in T1 oesophageal squamous cell carcinoma: implications for precision treatment strategy

Xue, Liyan; Zhao, Zitong; Wang, Minjie; Ma, Lan; Hua, Lin; Wang, Shaoming; Xue, Xuemin; Liu, Linxiu; Wang, Bingzhi; Li, Zhuo; Yang, Zhaoyang; Lu, Ning; Zhan, Qimin; Song, Yongmei

doi:10.1038/s41416-022-01997-y

Cited by 2 publications

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The tsRNA (tRNA‐GlyGCC‐5) was proven as a promising biomarker for diagnosis, prognosis, and adjuvant therapy selection [83]. According to the published work by Xue et al, serum miR‐20b‐5p was identified through microRNA (miRNA) array on T1 ESCC patients with ( n = 16) or without ( n = 14) lymph node metastasis (LNM), and transcriptome sequencing on 8 LN‐ and 8 LN+ ESCC serum exosome [84]. Further validation was carried out on 222 tumor samples and 229 serum samples from T1 ESCC patients, suggesting serum miR‐20b‐5p as a promising noninvasive biomarker for predicting LNM in T1 ESCC patients.…”

Section: Multiomics Advances In Cancer Subtypingmentioning

confidence: 99%

An overview of multiomics: a powerful tool applied in cancer molecular subtyping for cancer therapy

Zou,

Zhao,

Song

2023

Malignancy Spectrum

Self Cite

View full text Add to dashboard Cite

During the process of carcinogenesis and tumor progression, various molecular alternations occur in different omics levels. In recent years, multiomics approaches including genomics, epigenetics, transcriptomics, proteomics, metabolomics, single‐cell omics, and spatial omics have been applied in mapping diverse omics profiles of cancers. The development of high‐throughput technologies such as sequencing and mass spectrometry has revealed different omics levels of tumor cells or tissues separately. While focusing on a single omics level results in a lack of accuracy, joining multiple omics approaches together undoubtedly benefits accurate molecular subtyping and precision medicine for cancer patients. With the deepening of tumor research in recent years, taking pathological classification as the only criterion of diagnosis and predicting prognosis and treatment response is found to be not accurate enough. Therefore, identifying precise molecular subtypes by exploring the molecular alternations during tumor occurrence and development is of vital importance. The review provides an overview of the advanced technologies and recent progress in multiomics applied in cancer molecular subtyping and detailedly explains the application of multiomics in identifying cancer driver genes and metastasis‐related genes, exploring tumor microenvironment, and selecting liquid biopsy biomarkers and potential therapeutic targets.

show abstract

Section: Multiomics Advances In Cancer Subtypingmentioning

confidence: 99%

An overview of multiomics: a powerful tool applied in cancer molecular subtyping for cancer therapy

Zou,

Zhao,

Song

2023

Malignancy Spectrum

Self Cite

View full text Add to dashboard Cite

show abstract

Optimized tools and timing of response reassessment after neoadjuvant chemoradiation in rectal cancer

Chen

Zhang

et al. 2022

Int J Colorectal Dis

View full text Add to dashboard Cite

Purpose Reassessment tools of response to long-course neoadjuvant chemoradiation treatment (nCRT) in patients with locally advanced rectal cancer (LARC) are important in predicting complete response (CR) and thus deciding whether a wait-and-watch strategy can be implemented in these patients. Choosing which routine reassessment tools are optimal and when to use them is still unclear and will be researched in the study. Methods Altogether, 250 patients with LARC who received nCRT from 2013 to 2021 and were followed up were retrospectively reviewed. Common reassessment tools of response included digital rectal examination (DRE), clinical examination and symptoms, endoscopy, biopsy, magnetic resonance imaging (MRI), and blood biomarkers. Results Overall, 27.20% (68/250) patients had a complete response and 72.80% (182/250) did not. The combination of MRI, endoscopy, and biopsy showed the best performance in terms of accuracy of 74% and area under the curve (AUC, 0.714, 95% CI 0.546–0.882). Reassessing through DRE and presence of symptoms failed to improve the efficacy of response reassessment. After 100 days, biopsy as an assessment tool would obtain a substantial rise in accuracy from 51.28 to 100% ( p = 0.003). Conclusion The combination of MRI, endoscopy, and biopsy is suitable as the reassessment tool of response for applying a wait-and-watch strategy after long-course nCRT in patients with LARC. The accuracy of biopsy as reassessment tools would be improved if they were used over 100 days after nCRT in patients with rectal cancer. Supplementary Information The online version contains supplementary material available at 10.1007/s00384-022-04268-7.

show abstract

A liquid biopsy signature predicts lymph node metastases in T1 oesophageal squamous cell carcinoma: implications for precision treatment strategy

Cited by 2 publications

References 18 publications

An overview of multiomics: a powerful tool applied in cancer molecular subtyping for cancer therapy

An overview of multiomics: a powerful tool applied in cancer molecular subtyping for cancer therapy

Optimized tools and timing of response reassessment after neoadjuvant chemoradiation in rectal cancer

Contact Info

Product

Resources

About